Cancer Drugs Under Development

June 27th 2025

Practice-Changing Lung Cancer Data From the 2025 ASCO Annual Meeting

Findings from the phase 2b ASCEND trial will be presented at the European Society for Medical Oncology Gastrointestinal Cancers Congress on July 2, 2025.

Stephen Liu, MD, and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

Stephen V. Liu, MD;Joshua K. Sabari, MD

June 23rd 2025

Tigilanol Tiglate Exhibits Positive Efficacy in Soft Tissue Sarcoma

Stephen Liu, MD, and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

Twenty-two of 27 injected tumors across all patients with soft tissue sarcoma in the study showed complete or partial ablation.

PODCAST: ASCO 2025 Debrief: Key Updates in Genitourinary Cancer Management

Twenty-two of 27 injected tumors across all patients with soft tissue sarcoma in the study showed complete or partial ablation.

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD

June 19th 2025

Galleri Early Detection Test May Improve Cancer Detection vs SOC Alone

Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, discuss abstracts from the 2025 ASCO Annual Meeting that may impact genitourinary cancer care.

PATHFINDER 2 data build upon bolstered cancer detection rates by the multi-cancer early detection test found in a previously published PATHFINDER study.

FDA Grants RMAT Designation to Detalimogene in BCG-Unresponsive NMIBC

PATHFINDER 2 data build upon bolstered cancer detection rates by the multi-cancer early detection test found in a previously published PATHFINDER study.

Detalimogene voraplasmid demonstrated a 71% any-time CR rate in this non-muscle invasive bladder cancer population in the phase 1/2 LEGEND trial.

Tim Cortese

Certepetide Displays Positive Efficacy Trend in Metastatic PDAC

Detalimogene voraplasmid demonstrated a 71% any-time CR rate in this non-muscle invasive bladder cancer population in the phase 1/2 LEGEND trial.

Related Content

June 27th 2025

Practice-Changing Lung Cancer Data From the 2025 ASCO Annual Meeting

Findings from the phase 2b ASCEND trial will be presented at the European Society for Medical Oncology Gastrointestinal Cancers Congress on July 2, 2025.

Stephen V. Liu, MD;Joshua K. Sabari, MD

June 23rd 2025

Tigilanol Tiglate Exhibits Positive Efficacy in Soft Tissue Sarcoma

Stephen Liu, MD, and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

PODCAST: ASCO 2025 Debrief: Key Updates in Genitourinary Cancer Management

Twenty-two of 27 injected tumors across all patients with soft tissue sarcoma in the study showed complete or partial ablation.

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD

June 19th 2025

Galleri Early Detection Test May Improve Cancer Detection vs SOC Alone

Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, discuss abstracts from the 2025 ASCO Annual Meeting that may impact genitourinary cancer care.

FDA Grants RMAT Designation to Detalimogene in BCG-Unresponsive NMIBC

PATHFINDER 2 data build upon bolstered cancer detection rates by the multi-cancer early detection test found in a previously published PATHFINDER study.

Tim Cortese